Cover Image
Market Research Report

GLOBAL ANTITHROMBOTIC DRUGS MARKET FORECAST 2019-2027

Published by Inkwood Research Product code 633762
Published Content info 132 Pages
Delivery time: 2-3 business days
Price
Back to Top
GLOBAL ANTITHROMBOTIC DRUGS MARKET FORECAST 2019-2027
Published: August 19, 2019 Content info: 132 Pages
Description

KEY FINDINGS

The global antithrombotic drugs market is anticipated to flourish at a CAGR of 6.79% over the forecast period of 2019-2027. As per Inkwood Research, the market is expected to generate a revenue of $47953 million by the end of 2027. The global market growth is elevating owing to a surge in the knee and hip replacement surgeries and rising adoption rate of NOACs accompanied by other factors.

MARKET INSIGHTS

The antithrombotic drug market is segmented on the basis of antithrombotic drug types, which is sub-classified into anticoagulants, antiplatelet, and thrombin inhibitors. Over the coming years, factors like rising prevalence of coagulation disorders and increasing healthcare industries are anticipated to provide tremendous scope for the antithrombotic drugs market to expand. However, issues like patent expiration and lack of NOACS antidotes in the market are posing as challenges for the market.

REGIONAL INSIGHTS

Geographically, the global antithrombotic drugs market is divided into regions, namely Asia Pacific, Europe, North America, and Rest of the world segment that encompasses remaining countries. By the end of the forecast period, North America is anticipated to dominate this market because of flourishing growth antithrombotic agents and rising introduction of NOACs in the region.

COMPETITIVE INSIGHTS

The prominent players dealing in antithrombotic drugs market include GlaxoSmithKline PLC, Abbot Laboratories, Novartis AG, Bayer AG, Johnson & Johnson, Bristol-Myers Squibb Co., Sanofi SA, Baxter International Inc., Espero BioPharma, CSL Behring, Merck & Co. Inc., F. Hoffmann-La Roche Ltd., Boehringer Ingelheim GmbH, Eli Lilly and Company, Pfizer Inc., and Daiichi Sankyo Co. Ltd.

Table of Contents
Product Code: 16969

Table of contents

1. RESEARCH SCOPE

  • 1.1. STUDY GOALS
  • 1.2. SCOPE OF THE MARKET STUDY
  • 1.3. WHO WILL FIND THIS REPORT USEFUL?
  • 1.4. STUDY AND FORECASTING YEARS

2. RESEARCH METHODOLOGY

  • 2.1. SOURCES OF DATA
    • 2.1.1. SECONDARY DATA
    • 2.1.2. PRIMARY DATA
  • 2.2. TOP-DOWN APPROACH
  • 2.3. BOTTOM-UP APPROACH
  • 2.4. DATA TRIANGULATION

3. EXECUTIVE SUMMARY

  • 3.1. MARKET SUMMARY
  • 3.2. KEY FINDINGS
    • 3.2.1. ANTICOAGULANTS GENERATES THE HIGHEST REVENUE IN ANTITHROMBTIC MARKET
    • 3.2.2. ORAL ANTIPLATELETS ARE WIDELY USED
    • 3.2.3. DIRECT FACTOR XA INHIBITORS ARE ANTICIPATED TO GROW SIGNIFICANTLY DURING THE FORECAST PERIOD

4. MARKET DYNAMICS

  • 4.1. MARKET SCOPE & DEFINITION
  • 4.2. MARKET DRIVERS
    • 4.2.1. GROWING DEMAND FOR NOACS
    • 4.2.2. SURGE IN HIP AND KNEE REPLACEMENT SURGERIES
    • 4.2.3. HEALTHCARE POLICIES AND PROGRAMS BY GOVERNMENT
    • 4.2.4. GROWING AGING POPULATION
  • 4.3. MARKET RESTRAINTS
    • 4.3.1. HIGH COST OF NOACS
    • 4.3.2. LACK OF RESOURCES IN UNDERDEVELOPED COUNTRIES
  • 4.4. MARKET OPPORTUNITIES
    • 4.4.1. GROWING PREVALENCE OF COAGULATION DISORDERS
    • 4.4.2. GROWING HEALTHCARE INDUSTRIES
  • 4.5. MARKET CHALLENGES
    • 4.5.1. LACK OF NOACS ANTIDOTES IN THE MARKET
    • 4.5.2. PATENT EXPIRATION

5. MARKET BY ANTITHROMBOTIC DRUGS TYPE

  • 5.1. ANTICOAGULANTS
    • 5.1.1. ANTICOAGULANTS BY DRUGS TYPE
      • 5.1.1.1. LOW MOLECULAR WEIGHT HEPARIN
      • 5.1.1.2. ORAL ANTICOAGULANTS (VITAMIN K ANTAGONISTS)
    • 5.1.2. ANTICOAGULANTS BY RAPID ONSET ANTICOAGULANT (ROA)
      • 5.1.2.1. ORAL
      • 5.1.2.2. INJECTABLES
    • 5.1.3. ANTICOAGULANTS BY DRUG CLASS
      • 5.1.3.1. FACTOR XA
      • 5.1.3.2. DTIS
      • 5.1.3.3. HEPARIN
      • 5.1.3.4. VITAMIN K ANTAGONISTS
    • 5.1.4. ANTICOAGULANTS BY APPLICATIONS
      • 5.1.4.1. PE
      • 5.1.4.2. DVT
      • 5.1.4.3. AF
      • 5.1.4.4. OTHER ANTICOAGULANTS APPLICATIONS
  • 5.2. ANTIPLATELETS
    • 5.2.1. ORAL ANTIPLATELETS
    • 5.2.2. IV ANTIPLATELETS
  • 5.3. THROMBIN INHIBITORS
    • 5.3.1. DIRECT FACTOR XA INHIBITORS
    • 5.3.2. DIRECT THROMBIN INHIBITORS
    • 5.3.3. THROMBOLYTIC AGENTS

6. KEY ANALYTICS

  • 6.1. PORTER'S FIVE FORCES MODEL
    • 6.1.1. THREAT OF NEW ENTRANTS
    • 6.1.2. THREAT OF SUBSTITUTES
    • 6.1.3. BARGAINING POWER OF BUYERS
    • 6.1.4. BARGAINING POWER OF SUPPLIERS
    • 6.1.5. THREAT OF RIVALRY
  • 6.2. PATENT ANALYSIS
  • 6.3. MARKET TRENDS
    • 6.3.1. STRATEGIC ALLIANCE
    • 6.3.2. INCREASING FOCUS TOWARD EMERGING ECONOMIES
  • 6.4. KEY DRUGS IN ANTITHROMBIC DRUGS MARKET
  • 6.5. KEY BUYING CRITERIA
  • 6.6. OPPORTUNITY MATRIX

7. GEOGRAPHICAL ANALYSIS

  • 7.1. NORTH AMERICA
    • 7.1.1. THE UNITED STATES
    • 7.1.2. CANADA
  • 7.2. EUROPE
    • 7.2.1. THE UNITED KINGDOM
    • 7.2.2. FRANCE
    • 7.2.3. GERMANY
    • 7.2.4. SPAIN
    • 7.2.5. ITALY
    • 7.2.6. REST OF EUROPE
  • 7.3. ASIA PACIFIC
    • 7.3.1. INDIA
    • 7.3.2. CHINA
    • 7.3.3. JAPAN
    • 7.3.4. SOUTH KOREA
    • 7.3.5. AUSTRALIA
    • 7.3.6. REST OF APAC
  • 7.4. REST OF WORLD
    • 7.4.1. MIDDLE EAST AND AFRICA (MEA)
    • 7.4.2. LATIN AMERICA

8. COMPANY PROFILES

  • 8.1. ABBOT LABORATORIES
  • 8.2. ESPERO BIOPHARMA
  • 8.3. BAXTER INTERNATIONAL, INC.
  • 8.4. BAYER AG
  • 8.5. BOEHRINGER INGELHEIM GMBH
  • 8.6. BRISTOL-MYERS SQUIBB CO.
  • 8.7. CSL BEHRING
  • 8.8. DAIICHI SANKYO CO. LTD.
  • 8.9. ELI LILLY AND COMPANY
  • 8.10. F. HOFFMANN-LA ROCHE LTD.
  • 8.11. GLAXOSMITHKLINE PLC
  • 8.12. JOHNSON & JOHNSON
  • 8.13. MERCK & CO., INC.
  • 8.14. NOVARTIS AG
  • 8.15. PFIZER INC.
  • 8.16. SANOFI SA

LIST OF TABLES

  • TABLE 1 GLOBAL ANTITHROMBOTIC MARKET, BY REGION, 2019-2027 ($ MILLION)
  • TABLE 2 INDIAN GOVERNMENT INITIATIVES IN HEALTHCARE SECTOR
  • TABLE 3 GLOBAL ANTITHROMBOTIC DRUGS MARKET, BY TYPE, 2019-2027 ($ MILLION)
  • TABLE 4 GLOBAL ANTITHROMBOTIC DRUGS MARKET IN ANTICOAGULANTS, BY REGION, 2019-2027 ($ MILLION)
  • TABLE 5 GLOBAL ANTITHROMBOTIC DRUGS MARKET IN ANTICOAGULANTS, BY DRUGS TYPE 2019-2027 ($ MILLION)
  • TABLE 6 GLOBAL ANTICOAGULANTS MARKET IN LOW MOLECULAR WEIGHT HEPARIN, BY REGION, 2019-2027 ($ MILLION)
  • TABLE 7 LOVENOX DRUG BRAND
  • TABLE 8 GLOBAL ANTICOAGULANTS MARKET IN LOW ORAL ANTICOAGULANTS (VITAMIN K ANTAGONISTS), BY REGION, 2019-2027 ($ MILLION)
  • TABLE 9 GLOBAL ANTITHROMBOTIC DRUGS MARKET IN ANTICOAGULANTS, BY ROA, 2019-2027 ($ MILLION)
  • TABLE 10 GLOBAL ANTITHROMBOTIC DRUGS MARKET IN ANTICOAGULANTS, BY DRUG CLASS, 2019-2027 ($ MILLION)
  • TABLE 11 GLOBAL ANTITHROMBOTIC DRUGS MARKET IN ANTICOAGULANTS, BY APPLICATIONS, 2019-2027 ($ MILLION)
  • TABLE 12 GLOBAL ANTITHROMBOTIC DRUGS MARKET IN ANTIPLATELETS, BY REGION, 2019-2027 ($ MILLION)
  • TABLE 13 GLOBAL ANTITHROMBOTIC DRUGS MARKET IN ANTIPLATELETS, BY TYPES, 2019-2027 ($ MILLION)
  • TABLE 14 GLOBAL ANTIPLATELETS MARKET IN ORAL ANTIPLATELETS, BY REGION, 2019-2027 ($ MILLION)
  • TABLE 15 GLOBAL ANTIPLATELETS MARKET IN IV ANTIPLATELETS, BY REGION, 2019-2027 ($ MILLION)
  • TABLE 16 GLOBAL ANTITHROMBOTIC DRUGS MARKET IN THROMBIN INHIBITORS, BY REGION, 2019-2027 ($ MILLION)
  • TABLE 17 GLOBAL ANTITHROMBOTIC DRUGS MARKET IN THROMBIN INHIBITORS, BY TYPES, 2019-2027 ($ MILLION)
  • TABLE 18 NUMBER OF PATENTS ON ANTITHROMBOTICS AND ANTICOAGULANTS, BY VARIOUS COMPANIES, 2011-2016
  • TABLE 19 NUMBERS OF PATENTS ON ANTICOAGULANTS, BY VARIOUS COMPANIES, 2011-2016
  • TABLE 20 NORTH AMERICA ANTITHROMBOTIC DRUGS MARKET, BY COUNTRY, 2019-2027 ($ MILLION)
  • TABLE 21 EUROPE ANTITHROMBOTIC DRUGS MARKET, 2019-2027 ($ MILLION)
  • TABLE 22 ASIA PACIFIC ANTITHROMBOTIC DRUGS MARKET, 2019-2027 ($ MILLION)
  • TABLE 23 REST OF WORLD ANTITHROMBOTIC DRUGS MARKET, 2019-2027 ($ MILLION)

LIST OF FIGURES

  • FIGURE 1 GLOBAL ANTITHROMBOTIC MARKET, BY REGION, 2019-2027 ($ MILLION)
  • FIGURE 2 INDUSTRY IN THE WORLD IS RAPIDLY GROWING (%)
  • FIGURE 3 GLOBAL ANTITHROMBOTIC DRUGS MARKET IN ANTICOAGULANTS, 2019-2027 ($ MILLION)
  • FIGURE 4 BLOOD COAGULATION PROCESS
  • FIGURE 5 GLOBAL ANTICOAGULANTS MARKET IN ORAL, 2019-2027 ($ MILLION)
  • FIGURE 6 GLOBAL ANTICOAGULANTS MARKET IN INJECTABLES, 2019-2027 ($ MILLION)
  • FIGURE 7 GLOBAL ANTICOAGULANTS MARKET IN FACTOR XA, 2019-2027 ($ MILLION)
  • FIGURE 8 GLOBAL ANTICOAGULANTS MARKET IN DTIS, 2019-2027 ($ MILLION)
  • FIGURE 9 GLOBAL ANTICOAGULANTS MARKET IN HEPARIN, 2019-2027 ($ MILLION)
  • FIGURE 10 GLOBAL ANTICOAGULANTS MARKET IN VITAMIN K ANTAGONISTS, 2019-2027 ($ MILLION)
  • FIGURE 11 GLOBAL ANTICOAGULANTS MARKET IN PE, 2019-2027 ($ MILLION)
  • FIGURE 12 GLOBAL ANTICOAGULANTS MARKET IN DVT, 2019-2027 ($ MILLION)
  • FIGURE 13 GLOBAL ANTICOAGULANTS MARKET IN AF, 2019-2027 ($ MILLION)
  • FIGURE 14 GLOBAL ANTICOAGULANTS MARKET IN OTHER ANTICOAGULANTS APPLICATIONS, 2019-2027 ($ MILLION)
  • FIGURE 15 GLOBAL ANTITHROMBOTIC DRUGS MARKET IN ANTIPLATELETS, 2019-2027 ($ MILLION)
  • FIGURE 16 GLOBAL ANTITHROMBOTIC DRUGS MARKET IN THROMBIN INHIBITORS, 2019-2027 ($ MILLION)
  • FIGURE 17 GLOBAL THROMBIN INHIBITORS MARKET IN DIRECT FACTOR XA INHIBITORS, 2019-2027 ($ MILLION)
  • FIGURE 18 GLOBAL THROMBIN INHIBITORS MARKET IN DIRECT THROMBIN INHIBITORS, 2019-2027 ($ MILLION)
  • FIGURE 19 GLOBAL THROMBIN INHIBITORS MARKET IN THROMBOLYTIC AGENTS, 2019-2027 ($ MILLION)
  • FIGURE 20 PORTER'S FIVE FORCE MODEL
  • FIGURE 21 GLOBAL ANTITHROMBOTIC DRUGS MARKET, BY REGION, 2019-2027 ($ MILLION)
  • FIGURE 22 THE UNITED STATES ANTITHROMBOTIC DRUGS MARKET, 2019-2027 ($ MILLION)
  • FIGURE 23 CANADA ANTITHROMBOTIC DRUGS MARKET, 2019-2027 ($ MILLION)
  • FIGURE 24 THE UNITED KINGDOM ANTITHROMBOTIC DRUGS MARKET, 2019-2027 ($ MILLION)
  • FIGURE 25 FRANCE ANTITHROMBOTIC DRUGS MARKET, 2019-2027 ($ MILLION)
  • FIGURE 26 GERMANY ANTITHROMBOTIC DRUGS MARKET, 2019-2027 ($ MILLION)
  • FIGURE 27 SPAIN ANTITHROMBOTIC DRUGS MARKET, 2019-2027 ($ MILLION)
  • FIGURE 28 ITALY ANTITHROMBOTIC DRUGS MARKET, 2019-2027 ($ MILLION)
  • FIGURE 29 REST OF EUROPE ANTITHROMBOTIC DRUGS MARKET, 2019-2027 ($ MILLION)
  • FIGURE 30 INDIA ANTITHROMBOTIC DRUGS MARKET, 2019-2027($ MILLION)
  • FIGURE 31 CHINA ANTITHROMBOTIC DRUGS MARKET, 2019-2027($ MILLION)
  • FIGURE 32 JAPAN ANTITHROMBOTIC DRUGS MARKET, 2019-2027($ MILLION)
  • FIGURE 33 SOUTH KOREA ANTITHROMBOTIC DRUGS MARKET, 2019-2027($ MILLION)
  • FIGURE 34 AUSTRALIA ANTITHROMBOTIC DRUGS MARKET, 2019-2027($ MILLION)
  • FIGURE 35 REST OF APAC ANTITHROMBOTIC DRUGS MARKET, 2019-2027($ MILLION)
  • FIGURE 36 MIDDLE EAST AND AFRICA ANTITHROMBOTIC DRUGS MARKET, 2019-2027 ($ MILLION)
  • FIGURE 37 LATIN AMERICA ANTITHROMBOTIC DRUGS MARKET, 2019-2027 ($ MILLION)
Back to Top